The orphan nuclear receptor Nor1/Nr4a3 is a negative regulator of β-cell mass.


Journal

The Journal of biological chemistry
ISSN: 1083-351X
Titre abrégé: J Biol Chem
Pays: United States
ID NLM: 2985121R

Informations de publication

Date de publication:
29 03 2019
Historique:
received: 30 07 2018
revised: 15 01 2019
pubmed: 31 1 2019
medline: 17 10 2019
entrez: 31 1 2019
Statut: ppublish

Résumé

The Nr4a subfamily of nuclear receptor comprises three members in mammalian cells: Nur77/Nr4a1, Nurr1/Nr4a2, and Nor1/Nr4a3. Nr4a proteins play key roles in the regulation of glucose homeostasis in peripheral metabolic tissues. However, their biological functions in β-cells remain relatively uncharacterized. Here we sought to investigate the potential role of Nor1 in the regulation of β-cell mass and, in particular, β-cell survival/apoptosis. We used histological analysis to examine the consequences of genetic deletion of either

Identifiants

pubmed: 30696767
pii: S0021-9258(20)35542-3
doi: 10.1074/jbc.RA118.005135
pmc: PMC6442030
doi:

Substances chimiques

Cytokines 0
DNA-Binding Proteins 0
NR4A1 protein, human 0
NR4A3 protein, human 0
Nerve Tissue Proteins 0
Nr4a1 protein, mouse 0
Nr4a3 protein, mouse 0
Nuclear Receptor Subfamily 4, Group A, Member 1 0
Receptors, Steroid 0
Receptors, Thyroid Hormone 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4889-4897

Informations de copyright

© 2019 Close et al.

Références

Dev Biol. 2008 Jan 15;313(2):767-86
pubmed: 18096150
Science. 1995 Jul 28;269(5223):532-5
pubmed: 7624775
PLoS One. 2012;7(11):e51066
pubmed: 23226462
Cell Metab. 2006 Nov;4(5):339-40
pubmed: 17084708
Mol Endocrinol. 2013 Nov;27(11):1897-917
pubmed: 24065705
Nat Med. 2006 Sep;12(9):1048-55
pubmed: 16906154
Mol Cell Biol. 1999 Nov;19(11):7549-57
pubmed: 10523643
Biochem Biophys Res Commun. 2009 Aug 21;386(2):311-5
pubmed: 19523439
Science. 2005 Jan 21;307(5708):380-4
pubmed: 15662003
J Biol Chem. 2004 Jan 16;279(3):2005-11
pubmed: 14559918
Mol Metab. 2013 Jun 17;2(3):243-55
pubmed: 24044104
Oncogene. 2006 May 18;25(21):2974-86
pubmed: 16434970
PLoS One. 2013;8(1):e55035
pubmed: 23358114
Mol Endocrinol. 2012 Mar;26(3):372-84
pubmed: 22282471
Mol Cell Endocrinol. 2008 Nov 25;295(1-2):87-93
pubmed: 18809462
Cell. 1999 Apr 16;97(2):161-3
pubmed: 10219237
J Mol Endocrinol. 2006 Oct;37(2):317-26
pubmed: 17032747
FASEB J. 2005 Sep;19(11):1498-500
pubmed: 15985525
Diabetes. 2000 Mar;49(3):424-30
pubmed: 10868964
J Appl Physiol (1985). 2009 Jun;106(6):1826-31
pubmed: 19359610
Mol Cell Biol. 1993 Sep;13(9):5794-804
pubmed: 8395013
Int J Obes (Lond). 2012 Sep;36(9):1195-202
pubmed: 22143616
Diabetes Metab. 2013 Dec;39(6):478-84
pubmed: 24075454
J Clin Invest. 2002 Sep;110(6):851-60
pubmed: 12235117
J Biol Chem. 2007 Oct 26;282(43):31525-33
pubmed: 17785466
Cell. 2001 Feb 23;104(4):517-29
pubmed: 11239409
Biochim Biophys Acta. 2014 Nov;1843(11):2543-2555
pubmed: 24975497
Eur J Immunol. 2010 Jul;40(7):2041-9
pubmed: 20411565
Mol Endocrinol. 2007 Sep;21(9):2152-63
pubmed: 17550977
J Lipid Res. 2012 Dec;53(12):2610-9
pubmed: 23028113
Mol Endocrinol. 2010 Oct;24(10):1891-903
pubmed: 20392876
Biochem J. 2006 Feb 1;393(Pt 3):715-24
pubmed: 16223362
Proc Natl Acad Sci U S A. 2014 Apr 8;111(14):5242-7
pubmed: 24706823
Mol Endocrinol. 2012 Mar;26(3):399-413
pubmed: 22301783
Diabetologia. 2012 May;55(5):1346-54
pubmed: 22286529
PLoS One. 2014 Mar 17;9(3):e91462
pubmed: 24638142
Biochim Biophys Acta. 2009 Aug;1792(8):777-82
pubmed: 19447175
J Clin Invest. 2006 Jul;116(7):1802-12
pubmed: 16823478
BMC Med Genet. 2009 Aug 14;10:77
pubmed: 19682370
Diabetes Care. 2013 Aug;36 Suppl 2:S113-9
pubmed: 23882035
Diabetes. 2003 Jan;52(1):102-10
pubmed: 12502499
Mol Endocrinol. 2002 Jul;16(7):1638-51
pubmed: 12089357

Auteurs

Anne-Françoise Close (AF)

From the Department of AFNS, University of Alberta, Edmonton, Alberta T6G 2E1, Canada.
the Alberta Diabetes Institute, Edmonton, Alberta T6G 2E1, Canada.

Nidheesh Dadheech (N)

From the Department of AFNS, University of Alberta, Edmonton, Alberta T6G 2E1, Canada.
the Alberta Diabetes Institute, Edmonton, Alberta T6G 2E1, Canada.

Bárbara Scoralick Villela (BS)

From the Department of AFNS, University of Alberta, Edmonton, Alberta T6G 2E1, Canada.
the Alberta Diabetes Institute, Edmonton, Alberta T6G 2E1, Canada.

Claude Rouillard (C)

the Département de Psychiatrie et Neurosciences, Université Laval, Québec, Québec G1V 4G2, Canada, and.
the Centre de Recherche du CHU de Québec, Québec, Québec G1V 4G2, Canada.

Jean Buteau (J)

From the Department of AFNS, University of Alberta, Edmonton, Alberta T6G 2E1, Canada, jbuteau@ualberta.ca.
the Alberta Diabetes Institute, Edmonton, Alberta T6G 2E1, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH